FilingSEC EDGAR8-K
AEON Biopharma Announces FDA Meeting Feedback and Warrant Expiration Acceleration
· SEC accepted
StageDevelopment
Filing content
AEON Biopharma received FDA feedback on its ABP-450 development pathway, resulting in the accelerated expiration of its two-year milestone warrants to November 16, 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…